Laurus Labs Q1 net improves marginally

Satyanarayana Chava

Satyanarayana Chava

Drugmaker Laurus Labs said consolidated net profit rose close to 5% to ₹252.54 crore for the quarter ended June 2022, amid significant pricing pressure on key antiretroviral (ARV) APIs and the formulation business.

The growth on a 20% increase in revenue from operations to ₹1,540.69 crore (₹1,284.35 crore a year earlier). The performance reflects the company’s efforts towards strengthening and diversifying the business by sharpening focus on non-ARV APIs and formulations and high-growth CDMO segments, founder and CEO Satyanarayana Chava said in a release on Wednesday.

“Pricing pressure in ARV APIs and the Formulation business was significant during this quarter and ARV FDF volumes would increase in the coming quarters. The high-margin CDMO business growth helped the organisation deliver very good revenue and profit,” he said.

CFO V.V. Ravi Kumar said “EBITDA was at ₹454 crore with consistent EBITDA margins of 29.5% as better mix more than offset... depressed pricing in ARV business.” Capital expenditure during the quarter stood at ₹209 crore and the firm was on track to execute future capex as per schedule, he said.

Our code of editorial values

Related Topics
  1. Comments will be moderated by The Hindu editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.

Printable version | Jul 28, 2022 9:42:29 am |